Richard Daly

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA.

TAP Pharmaceutical Products, Inc. manufactures, develops, and markets pharmaceutical products. Its services include gastroenterology, gynecology, and urology. The company was founded in 1977 and is headquartered in Lake Forest, IL.

Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.

Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL.

Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The company is based in Wilmington, DE.

Part of BeyondSpring, Inc., BeyondSpring Pharmaceuticals, Inc. is a clinical-stage bio-pharmaceutical company that develops innovative immuno-oncology cancer therapies. The company is based in New York, NY. The company has a robust pipeline from internal development and collaboration with the University of Washington in de novo drug discovery using a ubiquitination platform. The CEO of the company is Lan Huang.